Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution

Author(s):  Marotta James C, Patel Gopesh, Carvalho Maria, Blakeney Samantha

Issue:  Jan/Feb 2020 - Volume 24, Number 1
View All Articles in Issue

Page(s):  69-76

Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution Page 1
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution Page 2
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution Page 3
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution Page 4
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution Page 5
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution Page 6
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution Page 7
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution Page 8

Download in electronic PDF format for $75

Abstract:  Androgenetic alopecia is the most common form of hair loss. This condition affects both men and women causing significant psychological distress and a decrease in the quality of life. The objective of this study was to investigate the clinical efficacy and patient satisfaction of a topical compounded formulation (minoxidil 10%, finasteride 0.1%, biotin 0.2%, and caffeine citrate 0.05% hydroalcoholic solution) in male androgenetic alopecia patients. A total of five individual, prospective case studies were conducted in the private hair transplant practice of Dr. James C. Marotta. Patients were provided with the topical formulation and instructed to apply a measured 1-mL dose to the entire frontal, parietal, and occipital scalp, twice daily for 6 months. Patients visited the practice periodically (90 days, 120 days, and 180 days post-treatment) for clinical evaluation, photographic assessment, and measurement of their treatment satisfaction by the Men’s Hair Growth Questionnaire. By the end of the study, at 180 days, the dermatologist-in-charge concluded that the topical treatment was successful for all five patients. Although moderate, the clinical improvements were visually noticeable as most patients had thicker, more voluminous hair; improved scalp coverage; and improved general hair appearance. These results were consistent with the photographic assessment, which demonstrated a global average increase of +1.05 in the patients’ hair density. According to the patients’ self-assessment, the topical compounded formulation was effective following 3 months and 6 months of continuous treatment. At 120 days, the patients’ satisfaction was neutral or negative, which was likely due to negligible differences in the patients’ hair growth and appearance in 90 days compared to 120 days. The results from this study suggest that the new hair-loss topical solution may be considered a safe and effective treatment option in male AGA patients.

Related Keywords: James C. Marotta, MD, FACS, Gopesh Patel, RPh, Maria Carvalho, PharmD, MRPharmS, PhD, Samantha Blakeney, topical preparation, male androgenetic alopecia, hair loss, minoxidil, finasteride, biotin, caffeine citrate, patient satisfaction, hair growth, quality of life, anti-androgenic agent, androgens, type II 5-alpha reductase, 5AR, vitamin B, formulation, clinical study

Related Categories: DERMATOLOGY, FORMULATIONS, PEER-REVIEWED, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, PATIENT ASSESSMENT

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Clinical Efficacy of a Topical Compounded Formulation in Male Androgenetic Alopecia: Minoxidil 10%, Finasteride 0.1%, Biotin 0.2%, and Caffeine Citrate 0.05% Hydroalcoholic Solution
Marotta James C
, Patel Gopesh, Carvalho Maria, Blakeney Samantha
Jan/Feb 2020
Pg. 69-76

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
Jul/Aug 2004
Pg. 269-274

Basics of Compounding for Cold Sores or Fever Blisters
Allen Loyd V Jr
May/Jun 2004
Pg. 206-209

Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy
Vigesaa Kristy A
, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
Jul/Aug 2004
Pg. 313-319

Minoxidil 3% and Finasteride 0.1% Topical Liquid
Allen Loyd V Jr
Mar/Apr 1999
Pg. 132

Basics of Compounding for Disorders of the External Ear
Allen Loyd V Jr
Jan/Feb 2004
Pg. 46-48

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Jul/Aug 2015
Pg. 295-300

The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP
Allen Loyd V Jr
May/Jun 2003
Pg. 180-183

Caffeine Citrate 10-mg/mL Oral Liquid
Allen Loyd V Jr
Jan/Feb 2007
Pg. 69

Extemporaneous Topical Minoxidil Solutions for the Treatment of Alopecia: Stability Studies and Incorporation Tests of Active Ingredients in ALOPLUS FAST Base
Spennacchio Antonio
, Lopedota Angela Assunta, Lopalco Antonio, Dibenedetto Maria Teresa, la Forgia Flavia Maria, Fontana Sergio, Franco Massimo, Denora Nunzio
May/Jun 2023
Pg. 256-262

Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Jan/Feb 2015
Pg. 6-12

Caffeine Citrate 20-mg/mL Injection
Allen Loyd V Jr
Mar/Apr 2012
Pg. 156

Basics of Compounding: Clinical Studies
Allen Loyd V Jr
Nov/Dec 2002
Pg. 443-447

Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women
Mason Dave
Jul/Aug 2002
Pg. 255-256

The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene
, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Jan/Feb 2014
Pg. 6-12

Stability Evaluation of Minoxidil in FOAMIL Form Base with Bracketing Study Design
Lupatini Rodrigo
, Sidhu Raman, Patel Harshad, Bichar Katia
May/Jun 2021
Pg. 236-240

Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
Sep/Oct 2020
Pg. 356

Novel Approaches to Topical Psoriasis Therapy
Koyama Gregory
, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Sep/Oct 2015
Pg. 357-365

Case Report: Diabetic Foot Ulcer Infection Treated with Topical Compounded Medications
Agbi Kelechi E
, Carvalho Maria, Phan Ha, Tuma Cristiane
Jan/Feb 2017
Pg. 22-27

Return to Top